

JUN 14 2004

06/14 '04 10:22

ID:3M 220-11-01

FAX:

PAGE 2

OFFICIAL


Application No.: 09/820,420

Docket No.: 55507US016

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Canceled)
2. (Currently Amended) A method of treating dermal lesions caused by venom-induced immune dysregulation, the method comprising applying a therapeutically effective amount of an immune response modifier compound to the site of the lesion, wherein the site of the lesion comprises a spider bite, and wherein the immune response modifier compound is a compound of Formula I



wherein

R₁ is selected from the group consisting of S and NR₃,

R₂ is selected from the group consisting of hydrogen, straight and branched chain alkyl containing one to six carbon atoms, and alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms; and


R₃ is selected from the group consisting of straight and branched chain alkyl containing one to six carbon atoms and straight or branched chain hydroxy alkyl containing one to six carbon atoms; or a pharmaceutically acceptable salt thereof.

3. (Original) The method of Claim 2 wherein R₁ is NR₃.
4. (Original) The method of Claim 2 wherein R₁ is S.
5. (Original) The method of Claim 2 wherein R₂ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, and ethoxymethyl.

Application No.: 09/820,420

Docket No.: 55507US016

6. (Original) The method of Claim 2 wherein R_3 is selected from the group consisting of 2-methylpropyl and 2-hydroxy-2-methylpropyl.
7. (Original) The method of Claim 2 wherein the IRM compound is selected from the group consisting of 4-amino-2-ethoxymethyl- α,α -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol, 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine, 2-methylthiazolo[4,5-*c*]quinolin-4-amine, 2-ethylthiazolo[4,5-*c*]quinolin-4-amine, 2-propylthiazolo[4,5-*c*]quinolin-4-amine and 2-butylthiazolo[4,5-*c*]quinolin-4-amine.
8. (Previously presented) The method of Claim 2 wherein the immune response modifier compound is applied via a cream or a gel.
- 9-14. (Canceled)
15. (Currently Amended) A method of inhibiting dermonecrosis caused by venom-induced immune dysregulation, the method comprising applying a therapeutically effective amount of an immune response modifier compound to the site of the venom-induced immune dysregulation, wherein the site of the venom-induced immune dysregulation comprises a spider bite, and wherein the immune response modifier compound is a compound of Formula I



I

wherein

 R_1 is selected from the group consisting of S and NR_3 ,

R_2 is selected from the group consisting of hydrogen, straight and branched chain alkyl containing one to six carbon atoms, and alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms; and

Application No.: 09/820,420

Docket No.: 55507US016

R_3 is selected from the group consisting of straight and branched chain alkyl containing one to six carbon atoms and straight or branched chain hydroxy alkyl containing one to six carbon atoms; or a pharmaceutically acceptable salt thereof.

16. (Original) The method of Claim 15 wherein R_1 is NR_3 .
17. (Original) The method of Claim 15 wherein R_1 is S.
18. (Original) The method of Claim 15 wherein R_2 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, and ethoxymethyl.
19. (Original) The method of Claim 15 wherein R_3 is selected from the group consisting of 2-methylpropyl and 2-hydroxy-2-methylpropyl.
20. (Original) The method of Claim 15 wherein the IRM compound is selected from the group consisting of 4-amino-2-ethoxymethyl- α,α -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol, 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine, 2-methylthiazolo[4,5-*c*]quinolin-4-amine, 2-ethylthiazolo[4,5-*c*]quinolin-4-amine, 2-propylthiazolo[4,5-*c*]quinolin-4-amine and 2-butylthiazolo[4,5-*c*]quinolin-4-amine.
21. (Previously presented) The method of Claim 15 wherein the immune response modifier compound is applied via a cream or a gel.
- 22-26. (Canceled)